CERIBELL INC
CBLLNASDAQTrading Snapshot
- Day Range
- $24.59 – $25.21
- 52-Week Range
- $10.85 – $25.63
- Volume
- $2.90B
- Avg Volume
- $2.86B
- Shares Outstanding
- 37.9M
- Next Earnings
- Dec 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $89M
- Last Q Revenue
- $28M
- P/E Ratio
- —
- P/S Ratio
- 8.9x
- EPS (TTM)
- $-1.76
- Dividend Yield
- —
- Dilution (1yr)
- +19.3%
Why Investors Own CBLL
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CERIBELL INC
CBLL
StockOtter · stockotter.spaceAbout CERIBELL INC
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL
BlackRock Inc. bought a new position in shares of CeriBell, Inc. (NASDAQ: CBLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor
Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL
Bank of America Corp DE boosted its holdings in CeriBell, Inc. (NASDAQ: CBLL) by 15.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. Th
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.